Identification of novel CD8+ T cell epitopes in human herpesvirus 6B U11 and U90

Mustafa Halawi1, Naeem Khan2, & Neil Blake1

1Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
2Department of Clinical Immunology, School of Immunity and Infection, University of Birmingham, Birmingham, UK

Keywords
HHV6B, T cells, CD8+, Epitopes, virus-infected cells

Abstract

Human herpesvirus 6B (HHV6B) infects over 90% of the population, and normally establishes a latent infection, where episodes of reactivation are asymptomatic. However, in immunocompromised patients HHV6B reactivation is associated with high morbidity and mortality. Cellular immunotherapy has been utilised against other herpesvirus in immunocompromised settings. However, limited information on the immune response against HHV6B has hampered the development of immunotherapy for HHV6B-driven disease. In this study, we have analysed the cellular immune response against four HHV6B antigens in a panel of 30 healthy donors. We show that the base-line level of T cell reactivity in peripheral blood is very low to undetectable. A short-term reactivation step enabled expansion of T cell responses, and all donors responded to at least 1 antigen, but more commonly 3 or 4. A hierarchy of immunogenicity was determined with antigens U90 and U54 being co-dominant, followed by U11 and U39. Putative CD8+ T cell epitopes were mapped to U90 and U11, predicted to be presented in the context of HLA-A1, A29, B39 and C6. T cells reactive against these novel epitopes were able to recognise virus-infected cells. Our data is supportive of the application and ongoing development of T cell immunotherapy against HHVB-driven disease in the immunocompromised host.

Introduction

Human herpesviruses are ubiquitous pathogens that generally cause self-limited disease in healthy individuals. However, in the context of an immunosuppressed host herpesvirus infection can lead to serious, often fatal disease [1]. Adoptive T cell therapy has been utilised as a therapeutic modality in immunocompromised individuals, such as recipients of hematopoietic stem cell (HSCT) or solid organ transplant (SOT), where the herpesviruses Epstein–Bar virus (EBV) and Human cytomegalovirus (HCMV) are important drivers of disease [2–9]. However, this has only been possible due to the in-depth knowledge and understanding of the cellular immune response against these viruses [10, 11]. This is in direct contrast to another herpesvirus, the β-herpesvirus human herpesvirus 6 (HHV6), which is also a significant pathogen associated with poor outcome in situations such as HSCT and SOT [12, 13]. HHV6 exists as two species, HHV6A and HHV6B, with a high level of nucleotide similarity [13–15]. The epidemiology and clinical features of HHV6A infection are poorly characterised [12]. By contrast, HHV6B is present worldwide with greater than 90% of the population carrying the virus [12]. Primary infection with HHV6B usually occurs during infancy, and is associated with a self-limiting disease, presenting as a febrile illness or exanthema subitum [16, 17]. After primary infection, HHV6B establishes a life-long latent infection, and in immunocompetent individuals reactivation is generally asymptomatic [12]. However, in an immunosuppressed patient, such as HSCT and SOT, reactivation of HHV6B is associated with significant clinical pathology, which includes graft versus host disease (GvHD) and encephalitis, and can lead to increased mortality [18–22]. Although assumed to be important for control of HHV6B reactivation, details of the cell-mediated immune response against HHV6B are only just beginning to be
elucidated. Recent studies have only just started to map and characterise the T cell responses against antigens from HHV6B. T cells have been shown to be reactive against antigens such as U11, U14, U54, U71 and U90, and HLA Class I restricted epitopes identified and mapped to HLA-A2, A3, B7 and B40 [23–26]. However, there is still a need to continue to fully characterise the immune responses to HHV6B and to expand the database of knowledge on T cell targets and HLA restricting elements.

In the current study, we have analysed a cohort of healthy donors for T cell responses to HHV6B antigens U90, U11, U54 and U39, representing an immediate early antigen, two viral tegument proteins and a viral envelope glycoprotein, respectively [15]. In agreement with other reports, we show that base-line levels of HHV6-specific T cells in peripheral blood is very low or undetectable, but that reactive T cells can be successfully expended in vitro by short-term stimulation with appropriate antigenic peptides. Indeed, of 30 donors analysed all were able to mount responses to at least one of the four target antigens, with the majority of donors responding to three or all four. We identify three novel putative CD8+ T cell epitopes in U90, predicted to be restricted through HLA-A1, -A29 and -B39, and one epitope in U11, restricted through HLA-C6. Importantly, T cells reactivated with these peptides were able to recognise HHV6B-infected target cells highlighting their potential clinical utility. The continual identification and characterisation of the targets of HHV6-specific T cells is important for the future development of T cell therapies against HHV6B driven disease, and the data presented here is an important addition.

Results

Ex vivo analysis of T cell responses to HHV6B U11, U39, U54 and U90

Very little is known about which HHV6B antigens are targeted by T cells during HHV6 infection, and how immunogenic such antigens would be. Given the high degree of homology between HHV6B and a second human β-herpesvirus, HCMV, we set out to determine if T cell responses could be detected directly ex vivo against HHV6B antigens corresponding to known immunogenic HCMV proteins. We focused on four antigens from HHV6B, namely U11, 39, U54 and U90, corresponding to HCMV antigens pp150, gB, pp65 and IE1. PBMCs were isolated from a panel of 30 donors, with a broad range of HLA backgrounds, stimulated for 16 h with single tube 15-mer PepMixes™ for each HHV6B antigen, and analysed for the frequency of CD8+ve, IFN-γ+ve and CD4+ve, IFN-γ+ve cells by ICS. A representative example of the flow cytometry analysis of HHV6 antigen-specific CD8+ve, IFN-γ+ve cells is shown in Figure 1.
for donor HD05 in Figure 1A. For this donor responses against the HHV6B antigens U11, U39 and U54 were equivalent to background unstimulated cells. A detectable response was seen against U90 (0.16%), although this was significantly lower than the representative HCMV antigen, IE1 (1.54%). Overall, for all donors the frequency of CD8+ T cells detected against the four HHV6B antigens was very low, in most cases barely above detected levels (Fig. 1B). The median values for U11, U39 and U54 were 0.00% IFNγ+ CD8+ T cells (ranges 0–0.04, 0–0.08, 0–0.1% respectively), whereas the median value for U90 was 0.01% (range 0–0.19%, n = 30). Only seven donors had levels detectable at 0.1% or above after subtraction of the unstimulated background, six for U90 (donors HD03, 0.1%; HD05, 0.13%; HD09, 0.19%; HD13, 0.14%; HD20, 0.14%; and HD30, 0.12%) and one for U54 (HD03, 0.1%). To ensure that this cohort of donors could respond to herpesviruses, 15 HCMV seropositive donors were also analysed for responses to four immunogenic antigens from HCMV (namely IE1, IE2, gB and pp65). Good responses were detected against IE1, pp65 and gB, with IE2 being recognised at low levels by a small number of donors in this group. Overall median values for the HCMV antigens were IE1 0.13%, IE2 0.00%, pp65 0.10% and gB 0.04% (ranges 0–1.5, 0–0.08, 0–1.9, 0–0.22% respectively, n = 15, Fig. 1B).

Similarly, very low levels of HHV6 antigen-specific CD4+ T cells were detected (Fig. 1C). The median values were U11 0% (range 0–0.01%), U39 0.01%, (0–0.03%), U54 0.02% (0–0.07%) and U90 0.01% (0–0.03%, n = 30). Responses to HCMV IE1, IE2, gB and pp65 were also measured, and found to be present at detectable levels in the majority of HCMV-seropositive donors tested, median values for IE1 0.07% (0–0.52%), IE2 0.02% (0–0.25%), pp65 0.4% (0.08–3.13%) and gB 0.24% (0–1.7%, n = 10, Fig. 1C).

**Short-term in vitro stimulation expands T cell responses against U11, U39, U54 and U90**

On the assumption that T cells against these HHV6B antigens were present but at barely detectable levels *ex vivo*, we predicted that a short-term *in vitro* reaction would expand these T cells such that we could begin to characterise the responses in further detail. Using the individual 15-mer PepMixes™ for U11, U39, U54 and U90, we stimulated PBMC from 25 donors for 10 days before analysis of expanded populations by direct ELISPOT using the PepMixes™. Figure 2A shows the data from 19 HCMV seropositive donors (top panel) and 6 HCMV seronegative donors (lower panel). We were able to detect IFNγ+ cells by ELISPOT against all antigens. In the HCMV seropositive donors, U90 showed the highest frequency of IFNγ+ cells, with a median value of 134 SFC/10⁵ input cells (range 0–376), with median responses to U54, U11 and U39 of 95
(range 0–346), 90 (range 0–372) and 50 (range 0–186) SFC/105 input cells, respectively (n = 19). We were able to expand HHV6B-specific T cells from the HCMV-seronegative donors supporting the conclusion that we are expanding authentic HHV6B response rather than cross-reactive HCMV T cells. There was a slight difference in the strength of responses detected in these donors, with U39 showing the strongest response with median value of 110 SFC/105 input cells (range 0–120), followed by U54 106 (range 39–149), U90 69 (range 10–286) and U11 53 (range 0–260) SFC/105 input cells (n = 6). However, when data from all donors were combined the median responses were U90 96 (range 0–376) SFC/105 input cells followed by U54 95 (range 0–346), U39 77 (range 0–186) and U11 66 (range 0–372) SFC/105 input cells. When analysed individually all donors responded to at least one antigen: 14 donors responded to all 4 antigens, 3 donors responded to 3 antigens, 6 responded to 2 and only 2 donors recognised only 1 (Fig. 2B). In total 21/25 donors showed some recognition of the antigens (84%) responded to both U54 and U90, 19/25 (76%) responded to U11 and 18/25 (74%) responded to U39. Based on the approaches used here, although the overall responses were similar, a hierarchy could be established with U90 and U54 being the most immunodominant, with very little difference between them, followed by U11 and U39.

Since the IFNγ ELISPOT does not discriminate between reactive CD8+ and CD4+ T cells we next performed phenotypic analyses of our polyclonal T cell populations (see Supporting information Fig. S1). This revealed that for each PepMix™ expanded T cell population, the majority of CD3+ T cells were also CD4+, with a mean frequency for U11 of 63.5 ± 10.8%; U39 66.3 ± 12.4%; U54 61.6 ± 12.9%; U90 65.9 ± 11.6% (n = 8). Correspondingly, lower values of CD3+CD8+ cells were seen in the expanded populations for each antigen, U11 21.5 ± 11.0%; U39 20 ± 8.9%; U54 27.9 ± 8.9%, U90 20.1 ± 9.1% (Fig. 2D).

Identification and HLA mapping of CD8+ T cell epitopes in U90

Having shown that the circulating precursor frequency of HHV6-directed T cells was low in peripheral blood, but that reactive cells could be readily expanded by a short-term stimulation in vitro, we next sought to identify and map individual CD8+ epitopes. Polyclonal T cell populations were expanded using the U90 PepMix™ from selected donors shown to contain U90-specific responses (Fig. 2). To ensure that we would maximise the possibility of identifying CD8+ responses, expanded T cells were enriched for CD8+ T cells by depletion of CD4+ cells. The first donor analysed was donor HD53 (HLA-A29, B44, C5, C16), with a fourfold enrichment of CD8+ T cells (increase from 16% to 67%) achieved by depleting CD4+ T cells (Supporting Information Fig. S2). These CD8-enriched cells were then analysed by ELISPOT for IFNγ+ve cells by direct stimulation with 33 U90 mini pools of overlapping 15-mer peptides. The results of the mini-pool screen are shown in Figure 3A, with two strong responses identified against pool 3 and 29. Using the 2D grid representing the U90 mini pools, the peptide that is present in both of these pools was identified as peptide 190, KPSKKKIKLDRPL (aa 766–780). The same expanded, CD8-enriched T cells were then screened against peptide 190 on its own, along with the flanking 15-mer peptides (189 and 191, Fig. 3B). This confirmed that peptide 190 was recognised by T cells from donor HD53, but neither 189 nor 191 (in agreement with the mini-pool screen data). To map the minimal peptide epitope, overlapping 9-mer peptides were synthesised spanning the peptide 190 sequence and tested by ELISPOT against CD8-enriched T cells which had been reactivated with the 15-mer peptide 190. Figure 3C shows that the minimal epitope maps to the sequence PSKSKKIKL (aa 765–773), termed PSK. To identify the HLA restricting element, autologous and partially HLA-matched target cells were pulsed with either the PSK peptide or DMSO control and used as targets in T cell assays with polyclonal T cell populations specific for PSK. Using detection of IFNγ secreted into the supernatant, we found that autologous and HLA-A29 matched targets were recognised by PSK-specific T cells, and while there was a slight recognition of B44-matched targets above background, we predict that the PSK peptide is presented to T cells in the context of HLA A29. One additional donor HLA-A29 positive donor was available and to test if this donor (HD33; HLA A11, A29, B39, B44, C9, C16) also responded to the PSK peptide, PBMCs were reactivated with the PSK peptide, cultured for 10 days in vitro before being screened by ELISPOT. A PSK-specific response was identified in this donor (Supporting Information Fig. S3), supporting this as a novel U90-derived CD8+ T cell epitope, putatively presented through HLA-A29.

Analysis of two further donors (HD10 and HD49) also identified novel CD8+ T cell epitopes. A mini-pool screen of expanded T cells, enriched for CD8+ cells, from donor HD10 (HLA A1, A2, B8, B39) identified a number of potential stimulating pools. The positive pools 5 and 31 were selected for further analysis, where the common 15-mer was peptide 226, EANHCFINHFVPIKT (aa 901–915, Supporting Information Fig. S4). Using peptide 226 and overlapping peptides spanning this sequence, the response was mapped to NHCFINHFV (NHC; aa 903–911), and shown to be restricted through HLA-B39 (Fig. 4A). Similar analysis of CD8-enriched cells from donor HD49 (HLA A1, A2, B8, B44, C5, C7) also identified a number of potential positive pools, with the responses to pools 2 and 24 selected for further analysis. The intersect between these pools was the 15-mer peptide 104, SICDLNIDPSESILL (aa 413–427, Supporting Information Fig. S4). Using peptide 104 and...
overlapping 9-mer peptides, the response was mapped to LNIDPSESI (LNI; aa 417–425), and shown to be restricted through HLA A1 (Fig. 4B).

Our analysis also confirmed responses to previously published epitopes as shown in Supporting Information Figure S5, where CD8-enriched T cells from donor HD57 (HLA A2, B40(60), B50, C6, C10) were shown to recognize the recently published B40-restricted peptides VEE (VEE; aa 39–47) and FESLLFPEL (FES; aa 57–67) [25]. (Supporting Information Fig. S5A and B). Two additional
B40-positive donors (HD05 and HD30) were also shown to have responses targeting these peptides (Supporting Information Fig. S5C).

Identification and HLA mapping of a CD8+ T cell epitope in U11

We applied the same strategy to mapping CD8+ T cell responses in HHV6B U11. Polyclonal T cell populations were expanded from donor HD32 (HLA-A1, A33, B37, B58, C6, C9), using the U11 PepMix™, enriched for CD8+ cells and analysed by ELISPOT for IFNγ+ve cells by stimulation with 30 U11 mini-pools of overlapping 15-mer peptides (Fig. 5A). A number of responses were identified, with two strong responses identified against pool 5 and 22 selected for further analyses. The intersect of these pools maps to 15-mer 85, PLKTQRRHKFPESDS (aa 337–351, Fig. 5A). This 15-mer was recognised by T cells, as was the 9-mer

**Figure 4.** Identification of HHV6B U90 CD8+ T cell epitopes NHCFINHFV and LNIDPSESI, presented through HLA B39 and A1. (A) U90 PepMix™ expanded T cells from donor HD10 (HLA-A1, A2, B8, B39) were depleted of CD4+ cells, before being tested in ELISPOT against individual overlapping 9-mer peptides spanning the 15-mer peptide 226 (EANHCFINHFVPIKT), identifying the minimal peptide as NHCFINHFV (left hand panel). Autologous or HLA-matched target cells were pulsed with either the NHCFINHFV 9-mer or DMSO, and used as targets in T cells assays with U90 PepMix™ expanded T cells, at an E/T ratio of 10:1 (right hand panel). T cell recognition of targets was monitored by detection of IFN-γ in culture supernatants by ELISA. (B) U90 PepMix™ expanded T cells from donor HD49 (HLA-A1, A2, B8, B44, C5, C7) were depleted of CD4+ cells, before being tested against individual overlapping 9-mer peptides spanning the 15-mer peptide 104 (SICDLNIDPSESILL), identifying the minimal peptide as LNIDPSESI (left hand panel). Autologous or partially HLA-matched target cells were pulsed with either the LNIDPSESI 9-mer or DMSO, and used as targets in T cells assays with U90 PepMix™ expanded T cells, at an E/T ratio of 20:1 (right hand panel). T cell recognition of targets was monitored by detection of IFN-γ in culture supernatants by ELISA. Results for ELISPOT experiments are presented as IFN-γ spot-forming cells (SCF) per 10^5 input cells and are shown as the mean of triplicate wells (±SD). Data from ELISA experiments are presented as pg/mL, and are shown as the mean of triplicate wells (±SD).
LKTQRRHKF (aa 338–346), termed LKT (Fig. 5B). Responses were also seen against other 9-mers (e.g. QRR and RRH), suggesting that this 15mer may contain a second independent epitope (Fig. 5B), but this was not investigated further. LKT-specific T cells were then shown to recognise peptide-pulsed target cells carrying both HLA-B37 and -C6 alleles (Fig. 5C). Based on the peptide binding motif of these alleles, where there is strong preference for a basic anchor residue at position 2 for HLA-C6 as opposed to an acidic residue for B37, we propose the HLA restricting element of LKT is HLA-C6.

HHV6B U90 and U11-specific T cells recognise virus-infected cells

With the ultimate objective of using these cells clinically, it was important to confirm that these new HHV6B-specific T cell epitopes could recognise endogenously expressed virus-infected cells.
antigen. Thus, T cell populations were expanded using individual 9-mers representing U90 PSK, LNI and NHC, and U11 LKT and the expanded T cells were tested for recognition of HHV6B-infected autologous cells lines. Figure 6A shows the data for U90 PSK, where there is clear recognition of HHV6B-infected cells to levels equivalent to peptide pulsed targets. Staining of target cells confirms that they are efficiently infected with HHV6B virus (Supporting Information Fig. S6). Target cell recognition for LNI, NHC and LKT effectors is shown in Figure 6B–D, with all T cell lines recognising HHV6B virus-infected cells to similar levels as the peptide-pulsed controls. Whilst the expanded T cell cultures used here will undoubtedly contain other non-HHV6B specific populations of T cells, we do not believe that they contribute to the recognition observed.

Discussion
HHV6B reactivation is a significant clinical problem after HSCT and SOT, and is associated with GvHD, encephalitis and increased mortality. Manipulation of cellular immune responses against other herpesviruses, such as EBV and HCMV, has proved to be successful in treating clinical disease driven by reactivation of these viruses in HSCT and SOT patients. This suggests that T cell immunotherapy should also be considered as a treatment option for patients with HHV6B reactivation after transplant. Currently, this is limited by a paucity of detailed information on the cellular immune response to this virus, such that although HHV6B is known to induce immune responses, there is little detailed information on target antigens, T cell epitopes or HLA restriction elements. This detail is a key requirement to understand the role of cellular immunity in controlling HHV6B reactivation, and will feed into development of future immunotherapy against this virus. In this report, we have investigated the T cell response to HHV6B infection in a group of healthy individuals, and mapped four putative novel CD8+ antigenic peptides to U90 and U11 predicted to be presented in the context of HLA alleles A1, A29, B39 and C6 (Table 1).

We started by addressing the level of HHV6-specific T cells in peripheral blood, against four antigens, U11, U39, U54 and U90. These antigens were chosen to represent antigens expressed immediately upon infection (U90) or present as part of the virion ( tegument proteins U11 and U54, and viral glycoprotein U39), and being functional homologues of immunogenic HCMV antigens (IE1, pp150, pp65 and gB, respectively) [15, 27]. After overnight stimulation with whole antigen PepMixes™, ICS was used to identify CD8+ IFNγ+ and CD4+ IFNγ+ T cells. In our panel of 30 healthy donors, responses were very low or undetectable. CD8+ IFNγ+ responses over 0.1% were only observed against U90 in six donors, and U54 in one donor, with median values of 0.01% for U90 and 0.00% for U11, U39 and U54. Levels of CD4+ IFNγ+ cells were also low but overall had higher median values for 3 out of the 4 antigens (U11 0.00%, U90 0.01%, U39 0.01% and U54 0.02%). In contrast, significant levels of HCMV IFNγ+ CD4+ and CD8+ responses to comparable antigens were observed in HCMV seropositive donors within this group. Thus, confirming we are able to detect herpesvirus-specific responses in our donors directly ex vivo, and that the very low levels of HHV6B-specific response are a feature of the immune response to HHV6B in these donors. Indeed, the levels of HHV6 T-cell reactivity detected in peripheral blood in study is in agreement with previous publications using viral infected cell lysates [23, 28–30] and more recently using a similar PepMix™ stimulation approach [25, 26]. It is known that T cell immunity to HCMV increases with age [31]. This has not yet been shown for HHV6B, and the age range of our cohort of donors, 22–63 years with a median of 39 years, was not sufficient to address this point. However, our study does indicate that the responses detectable in peripheral blood in the young (20–40 years) and middle aged (40–60

Figure 6. HHV6B U90- and U11-specific T cells recognise virus-infected target cells. (A) Polyclonal PSK-specific T cell effectors generated by reactivation of donor HD53 PBMC with the U90 9-mer peptide PSK were tested in T cell assays against autologous PHA blasts infected with HHV6B strain Z29 or mock infected, at the indicated E:T ratios. Control targets PHA blasts pulsed with either the PSK peptide or DMSO. (B and C) Polyclonal T cell effectors generated by reactivation of donor PBMC with the individual 9-mer peptides U90 9-mer NHC and LNI, and U11 LKT were tested in T cell assays against autologous PHA blasts infected with HHV6B strain Z29 or mock infected. Control targets PHA blasts pulsed with the individual 9-mer peptide or DMSO. T cells were used at an E/T ratio of 10:1. T cell recognition of target cells was determined by measuring release of IFNγ in to the supernatant by ELISA. Results are the mean of experimental triplicates (±SD) and expressed as pg/mL. 

© 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
to that seen when PepMix™ expanded cells were analysed for
Identification of HHV6B CD8⁺
maintaining the same approximate ratio that is present in
population, rather than also determining antigen specificity,
expanded by stimulation with PepMixes™ in vitro followed by
a short-term culture. Using this approach we did not
differentiate between CD4⁺ and CD8⁺ responses; however,
all 30 of the donors responded to at least one antigen, with
most (57%) responding to three or all four. Based on the
percentage of donors responding and median frequency of
IFNγ⁺ T cells, we observed a hierarchy of immunodominance
amongst these antigens, with U90 and U54 being co-dominant
followed by U11 and then U39. This is in general agreement
with a previous report where responses against five antigens
(U11, U15, U54, U71 and U90) were analysed in 14 donors,
and U90 was found to be the most immunogenic, followed by
U14 and then U54 [25]. It was not clear if the hierarchy
determined in our study was influenced by predominantly
antigen-specific CD4⁺ or CD8⁺ T cells, or an even
distribution of both. Although, when the PepMix™ expanded
cultures were analysed for the percentage of CD3⁺ CD4⁺ and
CD3⁺ CD8⁺ cells, we found that for all four antigens
the majority for cells were CD4⁺. Our analysis was limited to
measuring total CD4⁺ and CD8⁺ T cells in the expanded
population, rather than also determining antigen specificity,
and it could be argued that the CD4/8 T cell ratio observed in
the expanded population reflects a non-specific expansion
maintaining the same approximate ratio that is present in
PBMC. However, the mainly CD4⁺ T cell response was similar
to that seen when PepMix™ expanded cells were analysed for
frequency CD3⁺ CD4⁺ and CD3⁺ CD8⁺ cells based on production of IFNγ after antigenic stimulation [25] and also
in agreement with earlier reports [28–30, 32]. Regardless of
the exact composition of the expanded antigen-specific T cells,
our data strongly supports the inclusion of these HHV6B
antigens, particularly U90 and U54, in T cell immunotherapeutic
regimes.

Why the cellular immune response to this herpesvirus is
so low in peripheral blood of latently infected individuals is
unclear. It is likely that, in common with other herpesvirus
[33, 34], HHV6 will encode immunosuppressive proteins.
To date, one HHV6 protein, U21, has been shown to interfere with the MHC Class I antigen processing and
presentation pathway [35]. HHV6 has also been shown to
have immunomodulatory effects, including infection of
CD4⁺ T cells and induction of Treg cells [36–38]. These
factors may influence the development of HHV6-specific T
cell responses. The level of HHV6 reactivation may also play
a role. We assume the healthy individuals in this study have a
stable latent infection, and it may be that the levels of virus
reactivation from latency are insufficient to stimulate
generation of high numbers of T cells, while still controlling
reactivation. It would be of interest to carry out serial
analysis of selected donors over a period of time to measure
levels of HHV6-specific T cells, in parallel to monitoring
viral load. Analysis of T cell responses during primary
infection would be of central interest. Higher levels of
HHV6-specific T cells, than seen in healthy individuals, have
been detected in a HSCT patient with active HHV6B
reactivation [25], suggesting that active stimulation by
replicating HHV6B can induce expansion of virus-specific T
cells. A recent study by de Pagter et al. correlating HHV6
reactivation and levels of virus-specific T cells in patients
after HSCT supports this. These authors report that in HSCT
patients where HHV6 reactivation had been evident there
was also an expansion of HHV6-specific T cells, both CD4⁺
and CD8⁺ [39]. Thus, providing encouraging support for
the application of HHV6-specific T cell therapy either by
augmenting such responses by prophylactic treatment or by
adoptive T cell therapy. Indeed, Leen and colleagues have
recently reported the first successful use of HHV6-specific T
cells in adoptive T cell therapy in a patient with high levels of
HHV6 after HSCT [40]. Thus, supporting the need for
continued studies elucidating details of the immune
response to HHV6.

Identifying the immunogenic viral antigens is an impor-
tant first step for development of T cell immunotherapy.
However, it is also important to map and characterise T cell
epitopes within these viral antigens, particularly MHC Class
restricted peptides. Thus, we extended our study to begin
identifying HHV6B CD8⁺ T cell epitopes. We focussed on
donors known to respond to U90 and U11, and used an
unbiased approach with regard HLA background. After
stimulation with the relevant PepMix™, we depleted CD4⁺
T cells and screened for peptide reactive CD8⁺ T cells using
overlapping 15-mer libraries. We identified three putative
novel CD8+ T cell epitopes in U90, termed PSK, NHC and LNI. These epitopes were predicted to be restricted through HLA-A29, B39 and A1 respectively. The B39-restricted NHC epitope sequence conforms to the motif of peptides known to bind to HLA-B*3901, which have a highly conserved His at position 2, an aliphatic anchor at position 9 [41]. The LNI peptide, predicted to be restricted through HLA-A1, gave a weak response in comparison to the original 15-mer, and as HLA-A1 tends to have acidic residues at position 3, rather than position 4 for this peptide [41], it is possible that the real epitope begins NID and may be a 10-mer. Thus, we have termed this LNI peptide as a hypothetical epitope. We also found responses in three donors against the previously identified HLA B40(60)-restricted epitopes FES and VEE in U90 [25]. We also identified the epitope LKT in U11, which was presented by target cells that were HLA-B37, C6 positive. It is known that there is a strong genetic linkage between B*3701 and C*0602 [42]. Thus, based on characterised binding motifs, with B37 requiring an acidic anchor residue at position 2 and C6 a basic anchor residue at position 2 [41], and known antigenic peptides [43, 44] we predict that LKT is restricted through HLA-C7. These HLA alleles predicted to present the novel putative HHV6B T cell peptides are present in the caucasian population at average frequencies for A1 14.07%, A29 3.01%, B39 2.03% and C6 9.62% [45], highlighting their therapeutic relevance. Importantly, T cells specific for these novel HHV6B immunogenic peptides were also shown to recognise HHV6B-infected cells. It should be noted that the T cell populations generated will no doubt contain other non-HHV6B specific T cells that could contribute to the recognition observed. However, we do not believe that this has any significant impact on the data presented. Low background levels of recognition were observed, as expected utilising autologous PHA blasts as target cells in such assays, and a high percentage of virus infection was observed in all cases. Overall, this data supports the suitability of immunotherapeutic targeting of both U90 and U11 across a range of HLA backgrounds.

For the development and enhancement of adoptive T cell therapy approaches for diseases driven by HHV6B, a comprehensive understanding of the overall immune response to this virus and details such as target antigens and peptides, and HLA-restricting alleles is vital. The data presented in this report adds to and expands the existing information, and supports the on-going efforts to develop T cell immunotherapy for HHV6 reactivation in transplant settings.

Materials and Methods

Donors, cell lines and virus stocks

PBMCs were obtained from healthy adult volunteers, ranging in age from 22 to 63 years (median 39 years). The study was approved by the Liverpool Adult Research Ethics Committee and informed consent was obtained from all participating donors according to the Helsinki Declaration. PBMCs were isolated by Ficoll Hypaque density gradient centrifugation using Ficoll-Paque™ Plus (GE Healthcare Biosciences AB, Little Chalfont, UK). Donors were HLA typed using a PCR-based protocol by the Clinical Immunology Tissue Typing Laboratory, Royal Liverpool and Broad Green Hospital Trust, Liverpool, UK. In most cases, HLA types were obtained for A, B and C alleles, and provided to two-digit resolution. PHA blasts were generated from PBMC by treatment with 5 µg/mL PHA and culturing in T cell media (RPMI 1,640 medium with 5% human AB serum, 2 mM glutamine, 50 IU/mL penicillin and 50 µg/mL streptomycin). HHV6B virus (strain Z29) was generated as culture supernatant from SupT1/Z-29 cells [46], obtained from the HHV-6 Foundation (Santa Barbara, CA, USA). Briefly, HHV6B-Z29 infected SupT1 cells were maintained for 6 days in RPMI 1,640 media supplemented with 10% FCS and 2 mM glutamine. Virus-containing supernatant was then harvested, centrifuged at 400g for 5 min to remove cells, before being filtered through a 0.45 µm Minisart® NML Syringe Filter (Sartorius UK Ltd., Epsom, UK). Virus containing supernatant was stored in single use aliquots at −80°C.

Peptides

Single tube PepMixes™, containing 15-mer peptides (overlapping by 11aa) spanning the whole protein for HHV6B antigens U11, U39, U54 and U90, HCMV antigens IE1, IE2, pp65 and gB, and BK polyomavirus VP1 were obtained from JPT technologies (Berlin, Germany). Individual 15-mer peptides, overlapping by 11aa, for HHV6B antigens U11 and U90, were provided by Dr Ann Leen (Baylor College of Medicine, Houston, USA). The individual U11 and U90 15-mer peptides were used to generate mini-pools of 13–17 peptides, such that there were 30 mini pools for U11 and 33 for U90, with each 15-mer represented in 2 mini pools [47]. Individual 9-mer peptides for HHV6B U11 and U90 were purchased from Alta Bioscience Ltd. (Birmingham, UK). All peptides were synthesised at >70% purity, and stocks were dissolved in DMSO at 10 mg/mL and stored at −20°C

Intracellular cytokine staining

PBMCs (5 × 10⁶/mL) were incubated with PepMixes™ (final concentration 2 µg/ml) in a 5 ml polystyrene tube at 37°C for 2 h in T cell media, before addition of Brefeldin-A (10 µg/mL, Sigma, Gillingham, UK), and incubation continued for a further 14 h. Controls were unstimulated PBMC and PBMC stimulated with ConA (5 mg/mL). PBMCs were then washed twice with PBS at 4°C, pelleted...
and incubated with a PC5-conjugated anti-CD8 mAb (BD Biosciences, Oxford, UK) for 20 min at 4°C before being fixed with 4% paraformaldehyde. Cells were then permeabilised by incubation for 5 minutes with permeabilisation buffer (eBioscience, Hatfield, UK), followed by staining with a FITC-conjugated anti-IFN-γ mAb (BD Biosciences) for 30 min at 4°C in the dark. Cells were then washed twice with PBS, resuspended in 0.5 mL PBS, before 0.5 g for 30 min at 4°C, followed by staining with a bilised by incubation for 5 minutes with permeabilization buffer. Cells were then permea-

**ELISPOP**

ELISPOP analysis was carried out using the Human IFN-γ ELISPOP kit from MABTECH (Stockholm, Sweden). T cell populations were added to wells at known cell numbers in duplicate or triplicate in the presence of either PepMixes™, peptide mini pools or individual peptides, where the final concentration of each peptide was 2 µg/mL. Plates were incubated for 16 h, before addition of secondary antibody and subsequent detection reagents. The number of spot forming cells (SFC) was then determined manually. Controls in ELISPOP included unstimulated cells (DMSO treated) and cells stimulated with the BKV VP1 PepMix™.

**ELISA**

ELISA for human IFN-γ was carried out using an IFN-γ ELISA Ready-Set-Go™ set (eBioscience), according to the manufacturer’s guidance. Supernatants from T cell assays were measured directly or diluted as appropriate. Absorbance was read using a Multiskan Spectrum microplate reader (Thermo Scientific, Hemel Hempstead, UK) using Skanit software 2.2. The concentration of IFN-γ (pg/mL) in each sample was calculated against the standard curve.

**Generation of HHV6B-specific T cell lines**

Polyclonal HHV6-specific T cell populations were generated as follows. PBMCs (2 × 10^6) were incubated with PepMixes™ (where the final concentration of each peptide was 2 µg/mL) or individual peptides at a final concentration of 10 µg/mL in 100 µL RPMI for 60 min at 37°C. Cells were resuspended in T cell media and seeded in a 24-well plate. T cell cultures were supplemented on day 3 with 100 IU/mL IL-2 (Sigma), which was replenished every 3 days. On day 10 onwards T cells were harvested, counted and used in subsequent assays. CD8-enriched polyclonal T cell lines were generated from 10 days polyclonal T cell cultures by depletion of CD4+ T cells using an EasySep™ Human CD4 Positive Selection Kit (STEMCELL, Manchester, U.K.) according to the manufacturer’s instructions. The efficiency of CD8+ T cell enrichment was analysed by flow cytometry, and monitoring CD4+ depletion which ranged between 95% and 99%.

**Mapping T cell epitopes**

Mapping of minimal T cell epitopes was carried out by direct stimulation of expanded T cell populations, which had been enriched for CD8+ T cells. PBMCs were reactivated with individual 15-mer peptides, enriched for CD8+ T cells at day 10, before being incubated with overlapping 9-mer peptides representing the 15-mer peptide and analysis by ELISPOP.

**Identification of HLA restriction element**

Autologous, partially HLA-matched and HLA mis-matched PHA blasts or PBMCs were used as targets in T cell assays. Target cells were loaded with individual peptides (2 µg/mL) for 2 h in volume of 100 µL RPMI at 37°C, then washed 3 times with RPMI. Peptide-pulsed cells were then resus-
pended in T cell media at 1 × 10^5 cells/mL and used as targets in a T cell assay. Target cells (1 × 10^6 cells in 100 µL) were added in triplicate to wells of a 96-well V-bottom plate and 100 µL of T cells from short-term in vitro reactivations were added at an Effector-to-Target (E/T) ratio of 10:1. The effectors and targets were co-cultured overnight at 37°C, before 100 µL of supernatant was harvested and monitored for IFN-γ by ELISA.

**T cell recognition of HHV6B Z29-infected cells**

PHA blasts (2 × 10^6) in 500 µL T cell media were infected with 500 µL of HHV6B virus-containing supernatant for 90 min at 37°C. A further 1 mL T cell media was added and the infection continued. Six days after infection, virus-infected PHA blasts and comparable mock-infected cells were counted, resuspended in T cell media at 1 × 10^5 cells/mL and used as targets in a T cell assay. Target cells (1 × 10^5 cells in 100 µL) were added in triplicate to wells of a 96-well V-bottom plate and 100 µL of T cells from short-term in vitro reactivations were added at E/T ratios between 20:1 and 5:1. The effectors and targets were co-cultured overnight at 37°C, before 100 µL of supernatant was harvested and monitored for IFN-γ by ELISA. Infection of PHA blasts by HHV6B was confirmed by monitoring visually for cyto-
pathic effects and by immunofluorescence staining with a mouse-antihuman HHV6B mAb (monoclonal antibody MAB8535, clone C3108-003; Chemicon). The HHV6B mAb was used at a dilution of 1:50 in PBS, and incubated with cells for 90 min at 37°C in 5% CO2 before being stained with a secondary antibody (Goat anti-mouse IgG-FITC). Slides were counter stained DAPI then analysed with a Nikon fluorescence microscope.
Acknowledgments

We thank all donors for providing blood samples. We are grateful to Ann Leen (Baylor College of Medicine, Houston, USA) for kindly providing the individual 15-mer peptide libraries for HHV6B U11 and U90, and for comments on the manuscript. M.H. was funded by a scholarship from the Ministry of Higher Education, Kingdom of Saudi Arabia (JZU030).

Conflict of Interest

The authors declare no financial or commercial conflict of interest.

References

1. Bell, L. M. 1997. Herpesvirus infections in Immunocompromised Hosts. Sem. Pediatr. Infect. Dis. 8:169–177.
2. Boechk, M., W. Leisenring, S. Riddell, R. Bowden, M. Huang, D. Myers, T. Stevens-Ayers, M. E. D. Flowers, T. Cunningham, and L. Corey. 2003. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414.
3. Bollard, C.M., C. M. Rooney, and H. E. Heslop. 2012. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat. Rev. Clin. Oncol. 9:510–519.
4. Cobbold, M., N. Khan, B. Pourghysari, S. Tauro, D. McDonald, H. Osman, M. Assenmacher, L. Billingham, C. Steward, and C. Crawley, et al. 2005. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202:379–386.
5. Heslop, H. E., K. S. Slobod, M. A. Pule, G. A. Hale, A. Rousseau, C. A. Smith, C. M. Bollard, H. Liu, M-F. Wu, and R. J. Rochester, et al. 2010. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925–935.
6. Khanna, R., S. Bell, M. Sherritt, A. Galbraith, S.R. Burrows, L. Rafter, B. Clarke, R. Slaughter, M. C. Falk, and J. Douglas, et al. 1999. Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Nat Acad Sci USA 96:1039–10396.
7. Leen, A. M., G. D. Myers, U. Sili, M. H. Huls, H. Weiss, K. S. Leung, G. Carrum, R. A. Krance, C-C. Chang, and J. J. Molldrem, et al. 2006. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12:1160–1166.
8. Savoldo, B., J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y-F. Lin, R. E. Quiros-Tejeira, P. Reinke, and S. Schubert, et al. 2006. Treatment of solid organ transplant recipients with autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108:2942–2949.
9. Walter, E. A., P. D. Greenberg, M. J. Gilber, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038–1044.
10. Hislop, A. D., G. S. Taylor, D. Sauce, and A. B. Rickinson. 2007. Cellular Responses to Viral Infections in Humans: Lessons from Epstein-Barr Virus. Ann. Rev. Immunol. 25:587–617.
11. Crough, T, and R. Khanna. 2009. Immunobiology of human cytomegalovirus: from bench to beside. Clin. Micro. Rev. 22:76–98.
12. De Bolle, L., L. Naesens, and E. De Clercq. 2005. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin. Micro. Rev. 18:217–245.
13. Braun, D. K., G. Dominguez, and P. E. Pellett. 1997. Human herpesvirus 6. Clin. Micro. Rev. 10:521–567.
14. Gompels, U., J. Nicholas, G. Lawrence, M. Jones, B. Thomson, M. Martin, S. Efstathiou, M. Craxton, and H. A. Macaulay. 1995. The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution. Virology 209:29–51.
15. Dominguez, G., T.R. Dambaugh, F. R. Stamey, S. Dewhurst, N. Inoue, and P. E. Pellett. 1999. Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A. J. Virol. 73:8040–8052.
16. Okuno, T., K. Takahashi, K. Balachandra, K. Shiraki, K. Yamanishi, M. Takahashi, and K. Baba. 1989. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J. Clin. Micro. 27:651–653.
17. Yamanishi., K, K. Shiraki, T. Okuno, M. Takahashi, Y. Asano, and T. Kurata. 1988. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 331:1065–1067.
18. De Pagter, P., R. Schuurman, E. Meijer, D. Van Baarle, E.A. Sanders, and J. J. Boelens. 2008. Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. J. Clin. Virol. 43:361–366.
19. De Pagter, P., R. Schuurman, H. Visscher, M. De Vos, M. Bierings, A. M. van Loon, C. S. P. M. Uiterwaal, D. van Baarle, E. A. M. Sanders, and J. J. Boelens. 2008. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol. Blood Marrow Transplant 14:831–839.
20. Dulery, R., J. Salleron, A. Dewilde, J. Rossignol, E. M. Boyle, J. Gay, E. de Berranger, V. Coiteux, J-P. Jouet, and A. Duhamel, et al. 2012. Early Human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol. Blood Marrow Transplant 18:1080–1089.
21. Betts, B. C., J-A. H. Young, C. Ustun, Q. Cao, and D. J. Wiesdorf. 2011. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary. Biol. Blood Marrow Transplant 17:1546–1568.

22. Jaskula, E., D. Dlubek, M. Sedzimirska, D. Duda, A. Tarnowska, and A. Lange. 2010. Reactivation of cytomegalovirus, human herpesvirus 6, and Epstein–Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation. Transplant. Proc. 42:3273–3276.

23. Nastke, M-D., A. Becerra, L. Yin, O. Dominguez-Amoroco, L. Gibson, J. L. Stern, and J. M. Calvo-Calle. 2012. Human CD4+ T cell response to human herpesvirus 6. J Virol. 86:4776–4792.

24. Martin, L. K., A. Schub, S. Dillingerm, and A. Moosmann. 2012. Specific CD8+ T cells recognize human herpesvirus 6B. Eur. J. Immunol. 42:2901–2912.

25. Gerdemann, U., L. Keukens, J. M. Keirnan, U. L. Katari, C. T. Nguyen, A. P. de Pagter, C. A. Ramos, A. Kennedy-Nasser, S. M. Gottschalk, and H. E. Heslop, et al. 2013. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood 121:207–218.

26. Iampietro, M., G. Morissette, A. Gravel, I. Dubuc, M. Rousseau, A. Hasan, and R. J. O’Reilly, et al. 2014. Human herpesvirus 6B immediate-early I protein contains functional HLA-A* 02, HLA-A* 03, and HLA-B* 07 class I restricted CD8+ T-cell epitopes. Eur. J. Immunol. 44:3573–3584.

27. Sylwester, A. W., B. L. Mitchell, J. B. Edgar, C. Taormina, C. Pelte, F. Ruchti, P. R. Sleath, K. H. Grabstein, N. A. Hosken, and F. Kern, et al. 2005. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202:673–685.

28. Tejada-Simon, M. V., Y. C. Zang, J. Hong, V. M. Rivera, J. M. Killian, and J. Z. Zhang. 2002. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J. Virol. 76:6147–6154.

29. Yasukawa, M., Y. Yakushijin, M. Furukawa, and S. Fujita. 1993. Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. J. Virol. 67:6259–6264.

30. Yakushijin, Y., M. Yasukawa, and Y. Kobayashi. 1991. T-cell immune response to human herpesvirus-6 in healthy adults. Micro. Immunol. 35:655–660.

31. Khan, N., A. Hislop, N. Gudgeon, M. Cobbold, R. Khanna, L. Nayak, A. B. Richardson, and P. A. H. Moss. 2004. Herpesvirus-specific CD8 T cell immunity in old age: Cytomegalovirus impairs the response to coresident EBV infection. J. Immunol. 173:7481–7489.

32. Yakushijin, Y., M. Yasukawa, and Y. Kobayashi. 1992. Establishment and functional characterization of human herpesvirus 6-specific CD4+ human T-cell clones. J. Virol. 66:2773–2779.

33. Ressing, M. E., D. Horst, B. D. Griffin, J. Tellam, J. Zuo, R. Khanna, M. Rowe, and E. J. Wiertz. 2008. Epstein–Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products. Sem. Can. Biol. 18:397–408.

34. Noriega, V., V. Redmann, T Gardner, and D. Tortorella. 2012. Diverse immune evasion strategies by human cytomegalovirus. Immunol. Res. 54:140–151.

35. Glosson, N. L, and A. W. Hudson. 2007. Human herpesvirus 6A and-6B encode viral immunoevasins that downregulate class I MHC molecules. Virology 365:125–135.

36. Dagna, L., J. C. Pritchett, and P. Lusso. 2013. Immunomodulation and immunosuppression by human herpesvirus 6A and 6B. Future Virol. 8:273–287.

37. Takahashi, K., S. Sonoda, K. Higashi, T. Kondo, H. Takahashi, M. Takahashi, and K. Yamanishi. 1989. Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. J. Virol. 63:3161–3163.

38. Wang, F., J. Chi, G. Peng, F. Zhou, J. Wang, L. Li, D. Feng, F. Xie, B. Gu, and J. Qin, et al. 2014. Development of virus-specific CD4+ and CD8+ regulatory T cells induced by human herpesvirus 6 infection. J. Virol. 88:1011–1024.

39. de Pagter, A. P. J., J. J. Boelens, J. Scherrenburg, T. Vroom-de Blank, K. Tøselaa, N. Nanlohy, E. A. M. Sanders, R. Schuurman, and D. van Baarle. 2012. First analysis of human herpesvirus 6 T-cell responses: Specific boosting after HHV6 reactivation in stem cell transplantation recipients. Clin. Immunol. 144:179–189.

40. Papadopoulou, A., U. Gerdemann, U. Katari, I. Tzannou, H. Liu, C. Martinez, K. Leung, G. Carrum, A. P. Gee, and J. F. Vera, et al. 2014. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BK, and HHV6 infections after HSCT. Sci Transl Med 6:242ra83.

41. Rammensee, H.-G., J. Bachmann, N. N. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219.

42. Schmidt, A. H., D. Baier, U. V. Solloch, A. Stahr, N. Cereb, R. Blank, K. Tesselaar, N. Nanlohy, E. A. M. Sanders, R. Schuurman, and D. van Baarle. 2012. First analysis of human herpesvirus 6 T-cell responses: Specific boosting after HHV6 reactivation in stem cell transplantation recipients. Clin. Immunol. 144:179–189.

43. Kurilla, and A. B. Rickinson. 1997. Immediate early and early recognition. Blood 114:224–2253.

44. Steven, N. M., N. E. Annels, A. Kumar, A. M. Leese, M. G. Noriega, V., V. Redmann, T Gardner, and D. Tortorella. 2012. Diverse immune evasion strategies by human cytomegalovirus. Immunol. Res. 54:140–151.

45. Marsh, S. G. E., P. Parham, and L. D. Barber, 2000. The HLA facts book. London, Uk: Academic Press 2000.
46. Mayne, M., C. Cheadle, S. S. Soldan, C. Cermelli, Y. Yamano, N. Akhyani, and J. E. Nagel, et al. 2001. Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: induction of proinflammatory mechanisms. J. Virol. 75:11641–11650.

47. Kern, F., N. Faulhaber, C. Frömmel, E. Khatamzas, S. Prösch, C. Schönemann, I. Kretzschmar, R. Volkmer-Engert, H. D. Volk, and P. Reinke. 2000. Analysis of CD8 T cell reactivity to cytomegalovirus using protein spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 30:1676–1682.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher’s web-site.

Figure S1: A representative example of the flow cytometry analysis of the frequency of CD4+ and CD8+ T cells in a PepMix™ expanded T cell population.

Figure S2: A representative example of the flow cytometry analysis of the efficiency of CD4+ T cell depletion from PepMixTM expanded T cell population.

Figure S3: Environmental applications of organoclays for sorption of phenol and its derivatives.

Figure S4: Identification of a T cell response to HLA-A29 restricted T cell peptide PSKSKKIKL in donor HD33.

Figure S5: Identification of T cell responses to 15-mer peptide 226 in donor HD10 and peptide 104 in donor HD49.

Figure S6: Identification of T cell responses to HLA-B40 restricted T cell peptides VEESIKEL and FESLLFPEL.